To phase out D4T and stop the planned low dose D4T study in South Africa.
This petition had 59 supporters
People Living with HIV call on South African government to phase out D4T and the Wits Reproductive Health and HIV Institute to stop the planned low dose D4T vs Tenofovir study in South Africa.
As people living with HIV/AIDS in South Africa who are affected by (Stavudine) D4T find it very disturbing that our health facilities resort to the use of Stavudine when there are stock-outs of tenofovir. Additionally we have written a letter of concern to the principal investigator of the planned "low dose D4T vs. Tenofovir” study that it takes us backwards. Why are people living with HIV voices not consulted in the planning of this study?
We ask the Wits Reproductive Health and HIV initiative as you are aware as researchers in South Africa D4T is has more long term side effects than tenofovir why is this study planned in developing countries not in developed countries?
Many of us our bodies do not tolerate D4T as a result we are now stuck with the memories of what the side effects have done to our bodies. Moreover this limits our therapeutic durability and others amongst us who are not taking D4T have the best chance of successful treatment with their first-line regimen, making it critical that the medicines are as tolerable as possible. We want to stay for as long as possible to our first-line regimen hence we are encouraging and supporting each other to adhere to treatment so that we can delay the need to switch to more costly second-line which are complicated for us and our health care workers. Phase out D4T because the longer we remain on D4T which is most likely in poor resource settings who do not have access to viral load monitoring – the more our second-line options are compromised. A twice-daily dosing regimen (as with D4T 20 mg) is not have as simple as once-a day fixed-dose combination (as with tenofovir). People are more likely to adhere to simpler regimens and therefore are more likely to have better treatment outcomes, as well as limit resistance that requires more complex and expensive second-line regimens.
Today: Vuyiseka is counting on you
Vuyiseka Dubula-Majola needs your help with “PLHIV call on SA government and Wits Reproductive Health and HIV Institute: To phase out D4T and stop the planned low dose D4T study in South Africa.”. Join Vuyiseka and 58 supporters today.